Hong Kong-based biotech Regencell Bioscience Holdings experienced an extraordinary stock surge exceeding 64,000% during mid-2025 driven by retail speculation, social media hype, and a 38-for-1 stock split. Despite lacking FDA approval or commercial products, the stock’s volatility led to multiple trading halts, highlighting risks associated with meme-stock-style frenzies in emerging biotech ventures focused on Traditional Chinese Medicine for neurodevelopmental disorders.